Trials / Terminated
TerminatedNCT02808091
Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma
Phase II Trial of Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin (GIFOX-B)in Untreated NK/T Cell Lymphoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- National Cancer Centre, Singapore · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
* Assess responses, progression free survival (PFS) and overall survival (OS) of the combination of GIFOX-B chemotherapy with intensity-modulated radiation therapy (IMRT) in Stage IB or bulky disease - II and without IMRT in Stage III - IV. * Assess the toxicity and maximum tolerated dose of bortezomib administered in combination with GIFOX chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GIFOX-Bortezomib | GIFOX-Bortezomib will be given every 21 days for 4 cycles |
| DRUG | GIFOX-Bortezomib | GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles. |
| RADIATION | IMRT | a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks) |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2013-11-01
- Completion
- 2014-03-01
- First posted
- 2016-06-21
- Last updated
- 2016-09-05
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT02808091. Inclusion in this directory is not an endorsement.